Bradesco (B3: BBDC4, NYSE: BBD) reported Q1 2026 recurring net income of R$6.81 billion ($1.35B) on Wednesday May 6, up 16.1 percent year-on-year and 4.5 percent quarter-over-quarter, beating Bloomberg consensus of R$6.62 billion and LSEG’s R$6.7 billion estimate, according to the bank’s CVM filing.
Return on average equity reached 15.8 percent — beating the 15.2 percent analyst estimate by 0.6 percentage points — marking the ninth consecutive quarter of profit growth under CEO Marcelo Noronha’s “step-by-step” restructuring. The credit portfolio reached R$1.09 trillion (+8.4% YoY) with NPLs above 90 days at 4.2 percent. ADRs surged 3.37 percent in New York after-market trading following the release.
Key Points
What Bradesco Did in Q1 2026
“We delivered what we promised — another gradual increase in our profit. More important than a big step is the sustainability of our results. Even in a challenging macro scenario, we managed risks well and evolved,” CEO Marcelo Noronha stated in the earnings release. The comment captures the thesis precisely: Bradesco is not trying to match Itaú’s 26.4 percent ROE overnight but is demonstrating quarter-after-quarter improvement from the 10 percent ROE trough of early 2024 to 15.8 percent today — a 580 basis point improvement over nine quarters.
The margin performance was the standout. Total NII of R$20.05 billion grew 16.4 percent year-on-year and 4.2 percent quarter-over-quarter, driven by higher average loan volumes, improved liability margins, and wider spreads on client operations, according to the filing. Client NII of R$19.49 billion (+16.3% YoY) was the primary growth engine. Critically, market NII (treasury margin) reached R$553 million — positive and growing 19.7 percent year-on-year — in stark contrast to Santander Brasil, which reported a negative R$771 million treasury margin for the same quarter, per their respective CVM filings. Bradesco stated: “Our treasury margin delivered positive performance in a challenging macro scenario, revealing good risk management.”
Total revenue of R$36.9 billion rose 14 percent year-on-year, with fee and service income at R$10.3 billion (+6.2% YoY, -6.4% QoQ). The quarterly fee decline reflects seasonality, per the bank’s commentary. Positive highlights within fees included consortia, custody/brokerage, capital markets, and fund administration. Operating expenses of R$16.1 billion rose 7.8 percent year-on-year but fell 4.6 percent quarter-over-quarter, demonstrating the cost discipline that Noronha’s McKinsey-designed restructuring programme has imposed. “We are gaining productivity and increasing revenues in a diversified way. Today, we do more with less,” Noronha stated.
Why Bradesco’s Q1 Result Matters
The ROE convergence with Santander Brasil is the most significant development in the Q1 big-bank reporting season. A year ago, Bradesco’s 14.4 percent ROE trailed Santander’s 17.6 percent by 3.2 percentage points. In Q1 2026, the gap has narrowed to 0.2 percentage points (15.8 versus 16.0), according to the respective CVM filings. If the trend continues, Bradesco could overtake Santander in ROE by Q2 or Q3 — a milestone that seemed inconceivable during the 2023 crisis when Bradesco’s return fell to single digits. The narrowing also reflects Santander’s own deterioration (from 17.6 to 16.0) as the treasury margin collapse hit the Spanish-controlled bank harder.
The credit quality dynamics are where the complexity lies. NPLs above 90 days at 4.2 percent are stable — but the 26.5 percent year-on-year increase in PDD (provisions for doubtful loans) to R$9.67 billion signals that Bradesco is pre-provisioning for expected deterioration in the MSME (micro, small, and medium enterprise) portfolio. The bank acknowledged that the NPL uptick in MSMEs was “influenced by working capital operations with guarantees, which have a specific recovery dynamic.” This proactive provisioning — building reserves before losses materialise — is consistent with the “quality over growth” philosophy, but it also means the bank is consuming R$9.67 billion per quarter in provisioning expense, limiting the profit growth that the strong NII would otherwise deliver.
Bradesco Q1 2026 Quarterly Snapshot
| Indicator | Q1 2026 | Chg |
|---|---|---|
| Recurring Net Income | R$6.81 bn ($1.35B) | +16.1% YoY | +4.5% QoQ |
| ROAE | 15.8% | +1.4pp YoY | +0.6pp QoQ |
| Total NII | R$20.05 bn ($3.97B) | +16.4% YoY | +4.2% QoQ |
| Client NII / Market NII | R$19.49 bn / R$553 mn | +16.3% / +19.7% |
| Credit Portfolio | R$1.09 tn ($216B) | +8.4% YoY | +0.1% QoQ |
| NPL >90 Days | 4.2% | +0.1pp QoQ | -0.1pp YoY |
| PDD (Provisions) | R$9.67 bn ($1.91B) | +26.5% YoY | +9.5% QoQ |
| Total Revenue | R$36.9 bn ($7.31B) | +14% YoY |
| Basel Ratio | 17.4% | Comfortable (min: 11%) |
How Bradesco’s Result Reframes the Banking Sector
The Q1 2026 big-bank season now paints a clear three-tier picture: Itaú at 26.4 percent ROE (the undisputed leader), Bradesco and Santander in a virtual tie at 15.8/16.0 percent (with Bradesco accelerating and Santander decelerating), and Banco do Brasil in a separate public-bank category. The critical contrast is in treasury management: Bradesco delivered positive R$553 million in market NII while Santander swung to negative R$771 million — a R$1.3 billion gap on a single line that explains why Bradesco is narrowing the ROE differential despite having a lower absolute profit.
The BradSaúde spin-off is the structural catalyst that the market is beginning to price. The healthcare subsidiary — separated from Bradesco’s banking operations — delivered R$1.3 billion in profit in its first standalone quarter. Noronha’s characterisation of BradSaúde as “a historic step” with “incredible potential in health” signals that the bank intends to build a separate valuation for the healthcare franchise, which has been underappreciated within the consolidated banking multiple. Maria Estela Ferraz de Campos, head of credit at Integral Group, stated that “the plan continues to deliver results” and that the quarterly recovery is “consistent, focused on quality.”
What Happens Next for Bradesco
Conference call May 7: Analysts will focus on MSME credit quality trends, BradSaúde strategic roadmap, 2026 guidance refinement, and Desenrola 2.0 uptake.
Overtake Santander: At current ROE trajectories — Bradesco +1.4pp YoY vs Santander -1.6pp YoY — Bradesco could surpass Santander’s ROE by Q2 or Q3, per the filing data trends.
Provisioning peak: The 26.5 percent YoY PDD increase is the key variable. If MSME stress peaks and provisions stabilise, profit growth would accelerate mechanically. If stress worsens, the provisioning burden could cap ROE below 17 percent through 2026.
BradSaúde valuation: If the market begins to assign a separate healthcare multiple to BradSaúde’s R$1.3B quarterly profit (potentially 12–15x P/E for a Brazilian health insurer), the sum-of-parts valuation could provide significant upside beyond the current BBDC4 banking multiple, according to analyst commentary.
Frequently Asked Questions
Did Bradesco beat Q1 2026 estimates?
Bradesco Q1 2026 recurring profit of R$6.81 billion beat Bloomberg consensus of R$6.62 billion by 3 percent and LSEG’s R$6.7 billion estimate by 1.6 percent. ROAE of 15.8 percent beat the 15.2 percent analyst average by 0.6 percentage points. The result marks the ninth consecutive quarter of profit growth under CEO Marcelo Noronha.
How does Bradesco compare to Itaú and Santander now?
Bradesco’s 15.8 percent ROAE now trails Santander Brasil’s 16.0 percent by only 0.2 percentage points, having closed a 3.2 point gap over 12 months. Itaú leads at 26.4 percent, 10.6 points ahead of Bradesco. Bradesco’s positive market NII of R$553 million compares favourably to Santander’s negative R$771 million on the same line.
What is BradSaúde and why does it matter?
BradSaúde (B3: SAUD3) is Bradesco’s healthcare subsidiary, separated from the banking operations to unlock value. In its first standalone quarterly report, BradSaúde delivered R$1.3 billion in profit. CEO Noronha described it as “a historic step” with potential for separate valuation by the market, which could add to Bradesco’s sum-of-parts equity value beyond the banking multiple.
How did BBDC4 react to the earnings?
Bradesco’s ADRs surged 3.37 percent in New York after-market trading on Wednesday evening following the release. The strong reaction reflects the consensus beat, the ROE acceleration, and the BradSaúde value-unlock narrative. Six of seven analyst ratings surveyed by Broadcast recommend Buy for BBDC4.
Updated: 2026-05-06T20:00:00-03:00 by Rio Times Editorial Desk
Bradesco Q1 2026 | BBDC4 earnings results | Brazil bank ROE turnaround | NII margin | Latin American financial news | The Rio Times